CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Zolmitriptan intranasal. +1 moredrug
Likely dose
Zolmitriptan oral. 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06074016
NCT06074016Phase 1Completed

Pharmacokinetic Model Based on Population Physiology of Oral and Intranasal Formulations of Zolmitriptan in Healthy Volunteers

Parc de Salut Mar·interventional·Posted Oct 10, 2023·Updated May 5, 2026

In Brief

A Phase 1 clinical trial evaluating Zolmitriptan intranasal. and Zolmitriptan oral. for Healthy. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This is a phase I study to evaluate the PBPK of zolmitriptan intranasal versus oral administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSpain

Timeline

Phase 1CompletedFinished
202420252026
First PostedOct 10, 2023
Enrollment StartJul 12, 2023
Primary CompletionSep 6, 2023
Study CompletionSep 29, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.7 years ago

Interventions

Zolmitriptan intranasal.drug

Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.

Zolmitriptan oral.drug

Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.